**SUPPLEMENTAL DATA**

**Development and validation of a prediction score to avoid confirmatory testing in patients with suspected primary aldosteronism.**

Jacopo Burrello MD1\*, Martina Amongero MS2\*, Fabrizio Buffolo MD1, Elisa Sconfienza MD1, Vittorio Forestiero MD1, Alessio Burrello MS3, Christian Adolf MD4, Laura Handgriff MD4,

Martin Reincke MD4, Franco Veglio MD1, Tracy Ann Williams PhD1,4,

Silvia Monticone PhD1#, Paolo Mulatero MD1#.

(1) Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Torino, Italy. (2) Department of Mathematical Sciences G. L. Lagrange, Polytechnic University of Torino, Italy. (3) Department of Electrical, Electronic and Information Engineering "Guglielmo Marconi" (DEI), University of Bologna, Italy. (4) Medizinische Klinik und Poliklinik IV, Klinikum der Universität, Ludwig-Maximilians-Universität München, Munich, Germany.

\* Contributed equally and should be considered as joint first authors.

# Contributed equally and should be considered as joint last authors.

**Summary**

Table S1. Patient Characteristics of Study Cohort: Univariate Regression Analysis

Table S2. Patient Characteristics of Study Cohort: Multivariate Regression Analysis

Table S3. Characteristics of Training *versus* Internal Validation cohort

Table S4. Characteristics of Developmental *versus* Validation cohort

Table S5. Diagnostic performance of machine learning based models

Table S6. Score development and validation: optimization of sensitivity and specificity

Table S7. Distribution of PA patients according to the score

Figure S1. Flow chart for the management of PA patients

**Table S1. Patient Characteristics of Study Cohort: Univariate Regression Analysis**

|  |  |  |
| --- | --- | --- |
| **Variable (ref. PA confirmed)** | **OR (CI 95%)** | ***P-*value** |
| Age at diagnosis (years) | 0.99 (0.98-1.01) | 0.202 |
| Female sex, n (%) | 0.34 (0.24-0.46) | **<0.001** |
| Duration of HTN (months) | 1.01 (1.00-1.01) | 0.089 |
| Systolic BP (mmHg) | 1.01 (1.01-1.02) | **0.003** |
| Diastolic BP (mmHg) | 1.01 (1.00-1.03) | 0.052 |
| Antihypertensive medication (DDD) | 1.40 (1.27-1.54) | **<0.001** |
| BMI (Kg/sqm) | 1.02 (0.99-1.06) | 0.204 |
| PRA at screening (ng/mL/h) | 0.28 (0.14-0.57) | **<0.001** |
| Aldosterone at screening (ng/dL) | 1.06 (1.04-1.08) | **<0.001** |
| Lowest Potassium (mEq/L) | 0.13 (0.09-0.19) | **<0.001** |
| eGFR (mL/min) | 1.00 (0.99-1.01) | 0.666 |
| Diabetes, n (%) | 1.60 (0.82-3.12) | 0.166 |
| Organ damage, n (%) | 3.13 (2.28-4.29) | **<0.001** |
| CV events, n (%) | 2.16 (1.27-3.67) | **0.004** |

Odds ratio (OR) and the 95% confidence interval (CI) were evaluated by univariate logistic regression analysis for each variable. An OR greater than 1 indicates an increased likelihood of confirmed PA, and an OR less than 1 a decreased likelihood. HTN, Hypertension; BP, Blood Pressure; DDD, Defined Daily Dose (average maintenance dose per day for a drug used for its main indication in adults); PRA, Plasma Renin Activity; eGFR, estimated Glomerular Filtration Rate; CV, Cardiovascular. Organ damage is defined as presence of left ventricular hypertrophy at echocardiography and/or microalbuminuria.

**Table S2. Patient Characteristics of Study Cohort: Multivariate Regression Analysis**

|  |  |  |
| --- | --- | --- |
| **Variable (ref. PA confirmed)** | **OR (CI 95%)** | ***P-*value** |
| Female sex, n (%) | 0.42 (0.28-0.62) | **<0.001** |
| Systolic BP (mmHg) | 1.00 (0.99-1.01) | 0.566 |
| Antihypertensive medication (DDD) | 1.21 (1.07-1.36) | **0.002** |
| PRA at screening (ng/mL/h) | 0.07 (0.03-0.19) | **<0.001** |
| Aldosterone at screening (ng/dL) | 1.08 (1.06-1.11) | **<0.001** |
| Lowest Potassium (mEq/L) | 0.15 (0.09-0.23) | **<0.001** |
| Organ damage, n (%) | 2.64 (1.74-4.01) | **<0.001** |
| CV events, n (%) | 1.40 (0.72-2.72) | 0.315 |

Odds ratio (OR) and the 95% confidence interval (CI) were evaluated by multivariate logistic regression analysis for variables associated to a confirmed PA diagnosis in the univariate model. An OR greater than 1 indicates an increased likelihood of confirmed PA, and an OR less than 1 a decreased likelihood. BP, Blood Pressure; DDD, Defined Daily Dose (average maintenance dose per day for a drug used for its main indication in adults); PRA, Plasma Renin Activity; CV, Cardiovascular. Organ damage is defined as presence of left ventricular hypertrophy at echocardiography and/or microalbuminuria.

**Table S3. Characteristics of Training versus Internal Validation cohort**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **Combined Cohort**  **(n=696)** | **Training Cohort**  **(n=522)** | **Validation Cohort**  **(n=174)** | ***P-*value** |
| Confirmed PA, n (%) | 421 (60.5) | 322 (61.7) | 99 (56.9) | 0.263 |
| Subtyping, UPA (%) | 133 (19.1) | 98 (18.8) | 35 (20.1) | 0.313 |
| Age at diagnosis (years) | 50 ± 9.9 | 50 ± 10.2 | 50 ± 9.3 | 0.770 |
| Female sex, n (%) | 318 (45.7) | 239 (45.8) | 79 (45.4) | 0.930 |
| Duration of HTN (months) | 64 [21; 131] | 59 [21; 128] | 75 [23; 134] | 0.300 |
| Systolic BP (mmHg) | 155 ± 20.3 | 155 ± 20.4 | 155 ± 20.2 | 0.889 |
| Diastolic BP (mmHg) | 95 ± 11.0 | 95 ± 11.1 | 94 ± 10.8 | 0.531 |
| Antihypertensive medication (DDD) | 2.15 [1.00; 4.00] | 2.00 [1.00; 3.69] | 2.33 [1.00; 4.00] | 0.765 |
| BMI (Kg/sqm) | 25.7 ± 4.28 | 25.9 ± 4.23 | 25.4 ± 4.45 | 0.224 |
| PRA at screening (ng/mL/h) | 0.30 [0.15; 0.40] | 0.22 [0.15; 0.40] | 0.30 [0.20; 0.45] | 0.086 |
| Aldosterone at screening (ng/dL) | 25.6 [18.7; 35.5] | 25.8 [18.8; 35.5] | 24.3 [18.5; 35.1] | 0.791 |
| Lowest Potassium (mEq/L) | 3.8 ± 0.62 | 3.8 ± 0.62 | 3.8 ± 0.61 | 0.414 |
| eGFR (mL/min) | 91 ± 17.0 | 91 ± 17.2 | 91 ± 16.6 | 0.914 |
| Diabetes, n (%) | 44 (6.3) | 33 (6.3) | 11 (6.3) | 1.000 |
| Organ damage, n (%) | 404 (58.0) | 298 (57.1) | 106 (60.9) | 0.375 |
| CV events, n (%) | 81 (11.6) | 62 (11.9) | 19 (10.9) | 0.733 |

Characteristics of patients included in the developmental cohort: patients from the combined cohort (n=696) were randomly assigned to training (n=522), or validation cohort (n=174). HTN, Hypertension; BP, Blood Pressure; DDD, Defined Daily Dose (average maintenance dose per day for a drug used for its main indication in adults); PRA, Plasma Renin Activity; eGFR, estimated Glomerular Filtration Rate; CV, Cardiovascular. Organ damage is defined as presence of left ventricular hypertrophy at echocardiography and/or microalbuminuria. Normally and non-normally distributed variables were reported as mean ± standard deviation or median [interquartile range], respectively. Categorical variables were reported as absolute number (n) and proportion (%).

**Table S4. Characteristics of Developmental versus Validation cohort**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Developmental Cohort**  **(n=696)** | **External Validation Cohort**  **(n=328)** | ***P-*value** |
| Confirmed PA, n (%) | 421 (60.5) | 173 (52.7) | **0.019** |
| Subtyping, UPA (%) | 133 (19.1) | 89 (27.1) | 0.299 |
| Age at diagnosis (years) | 50 ± 9.9 | 50 ± 13.5 | 0.467 |
| Female sex, n (%) | 318 (45.7) | 192 (58.5) | **<0.001** |
| Duration of HTN (months) | 64 [21; 131] | 48 [11; 138] | **0.006** |
| Systolic BP (mmHg) | 155 ± 20.3 | 150 ± 19.6 | **<0.001** |
| Diastolic BP (mmHg) | 95 ± 11.0 | 93 ± 12.4 | 0.136 |
| Antihypertensive medication (DDD) | 2.15 [1.00; 4.00] | 1.00 [0.00; 2.50] | **<0.001** |
| BMI (Kg/sqm) | 25.7 ± 4.28 | 27.0 ± 5.09 | **<0.001** |
| PRA at screening (ng/mL/h) | 0.30 [0.15; 0.40] | N.A. | N.A. |
| DRC at screening  (mU/L) | N.A. | 2.7 [2.0; 5.6] | N.A. |
| Aldosterone at screening (ng/dL) | 25.6 [18.7; 35.5] | 12.8 [8.2; 20.0] | **<0.001** |
| Lowest Potassium (mEq/L) | 3.8 ± 0.62 | 3.5 ± 0.51 | **<0.001** |
| eGFR (mL/min) | 91 ± 17.0 | 87 ± 19.9 | **0.001** |
| Diabetes, n (%) | 44 (6.3) | 36 (11.0) | **0.010** |
| Organ damage, n (%) | 404 (58.0) | 129 (39.3) | **<0.001** |
| CV events, n (%) | 81 (11.6) | 39 (11.9) | 0.907 |

Characteristics of patients included in the analysis: patients from the developmental cohort from Torino (n=696) were compared to patients from the external validation cohort from Munich (n=328). HTN, Hypertension; BP, Blood Pressure; DDD, Defined Daily Dose (average maintenance dose per day for a drug used for its main indication in adults); PRA, Plasma Renin Activity; eGFR, estimated Glomerular Filtration Rate; CV, Cardiovascular. Organ damage is defined as presence of left ventricular hypertrophy at echocardiography and/or microalbuminuria. Normally and non-normally distributed variables were reported as mean ± standard deviation or median [interquartile range], respectively. Categorical variables were reported as absolute number (n) and proportion (%).

**Table S5. Diagnostic performance of machine learning based models**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **PACT Score Accuracy** | | | **Predicted Diagnosis** | | | **Performance** | | |
| **LDA Model** | **Training cohort** (N = 522) | PA confirmed | | PA excluded | Accuracy (%) | | 79.7 |
| PA confirmed | 272 | | 50 | Sensitivity (%) | | 84.5 |
| PA excluded | 56 | | 144 | Specificity (%) | | 72.0 |
| **Validation cohort** (N = 174) | PA confirmed | | PA excluded | Accuracy (%) | | 77.6 |
| PA confirmed | 82 | | 17 | Sensitivity (%) | | 82.8 |
| PA excluded | 22 | | 53 | Specificity (%) | | 70.7 |
| **Combined cohort** (N = 696) | PA confirmed | | PA excluded | Accuracy (%) | | 79.2 |
| PA confirmed | 354 | | 67 | Sensitivity (%) | | 84.1 |
| PA excluded | 78 | | 197 | Specificity (%) | | 71.6 |
| **RF Model** | **Training cohort** (N = 522) | PA confirmed | | PA excluded | Accuracy (%) | | 82.8 |
| PA confirmed | 286 | | 36 | Sensitivity (%) | | 88.8 |
| PA excluded | 54 | | 146 | Specificity (%) | | 73.0 |
| **Validation cohort** (N = 174) | PA confirmed | | PA excluded | Accuracy (%) | | 79.9 |
| PA confirmed | 84 | | 15 | Sensitivity (%) | | 84.8 |
| PA excluded | 20 | | 55 | Specificity (%) | | 73.3 |
| **Combined cohort** (N = 696) | PA confirmed | | PA excluded | Accuracy (%) | | 82.0 |
| PA confirmed | 370 | | 51 | Sensitivity (%) | | 87.9 |
| PA excluded | 74 | | 201 | Specificity (%) | | 73.1 |
| **Linear SVM** | **Training cohort** (N = 522) | PA confirmed | | PA excluded | Accuracy (%) | | 80.7 |
| PA confirmed | 272 | | 50 | Sensitivity (%) | | 84.5 |
| PA excluded | 51 | | 149 | Specificity (%) | | 74.5 |
| **Validation cohort** (N = 174) | PA confirmed | | PA excluded | Accuracy (%) | | 78.2 |
| PA confirmed | 82 | | 17 | Sensitivity (%) | | 82.8 |
| PA excluded | 21 | | 54 | Specificity (%) | | 72.0 |
| **Combined cohort** (N = 696) | PA confirmed | | PA excluded | Accuracy (%) | | 80.0 |
| PA confirmed | 354 | | 67 | Sensitivity (%) | | 84.1 |
| PA excluded | 72 | | 203 | Specificity (%) | | 73.8 |
| **Gaussian SVM** | **Training cohort** (N = 522) | PA confirmed | | PA excluded | Accuracy (%) | | 83.9 |
| PA confirmed | 284 | | 38 | Sensitivity (%) | | 88.2 |
| PA excluded | 46 | | 154 | Specificity (%) | | 77.0 |
| **Validation cohort** (N = 174) | PA confirmed | | PA excluded | Accuracy (%) | | 74.7 |
| PA confirmed | 81 | | 18 | Sensitivity (%) | | 81.8 |
| PA excluded | 26 | | 49 | Specificity (%) | | 65.3 |
| **Combined cohort** (N = 696) | PA confirmed | | PA excluded | Accuracy (%) | | 81.6 |
| PA confirmed | 365 | | 56 | Sensitivity (%) | | 86.7 |
| PA excluded | 72 | | 203 | Specificity (%) | | 73.8 |

The table shows real and predicted diagnosis (PA confirmed vs. excluded), accuracy, sensitivity, specificity for the training cohort (n=522), the validation cohort (n=174), and the combined cohort from Torino (n=696). Diagnostic performance is shown for LDA (linear discriminant analysis), RF (random forest), linear and gaussian SVM (support vector machine) models.

**Table S6. Score development and validation**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **PACT Score Accuracy** | | **Predicted Diagnosis** | | **Performance** | |
| **Real Diagnosis (Cut-off ≥5)** | **Training cohort** (N = 522) | PA confirmed | PA excluded | Accuracy (%) | 70.7 |
| PA confirmed | 322 | 0 | Sensitivity (%) | 100.0 |
| PA excluded | 153 | 47 | Specificity (%) | 23.5 |
| **Validation cohort** (N = 174) | PA confirmed | PA excluded | Accuracy (%) | 66.1 |
| PA confirmed | 99 | 0 | Sensitivity (%) | 100.0 |
| PA excluded | 59 | 16 | Specificity (%) | 21.3 |
| **Combined cohort** (N = 696) | PA confirmed | PA excluded | Accuracy (%) | 69.5 |
| PA confirmed | 421 | 0 | Sensitivity (%) | 100.0 |
| PA excluded | 212 | 63 | Specificity (%) | 22.9 |
| **Real Diagnosis (Cut-off ≥8)** | **Training cohort** (N = 522) | PA confirmed | PA excluded | Accuracy (%) | 84.1 |
| PA confirmed | 297 | 25 | Sensitivity (%) | 92.2 |
| PA excluded | 58 | 142 | Specificity (%) | 71.0 |
| **Validation cohort** (N = 174) | PA confirmed | PA excluded | Accuracy (%) | 83.9 |
| PA confirmed | 91 | 8 | Sensitivity (%) | 91.9 |
| PA excluded | 20 | 55 | Specificity (%) | 73.3 |
| **Combined cohort** (N = 696) | PA confirmed | PA excluded | Accuracy (%) | 84.1 |
| PA confirmed | 388 | 33 | Sensitivity (%) | 92.2 |
| PA excluded | 78 | 197 | Specificity (%) | 71.6 |
| **Real Diagnosis (Cut-off ≥13)** | **Training cohort** (N = 522) | PA confirmed | PA excluded | Accuracy (%) | 53.6 |
| PA confirmed | 80 | 242 | Sensitivity (%) | 24.8 |
| PA excluded | 0 | 200 | Specificity (%) | 100.0 |
| **Validation cohort** (N = 174) | PA confirmed | PA excluded | Accuracy (%) | 55.2 |
| PA confirmed | 21 | 78 | Sensitivity (%) | 21.2 |
| PA excluded | 0 | 75 | Specificity (%) | 100.0 |
| **Combined cohort** (N = 696) | PA confirmed | PA excluded | Accuracy (%) | 54.0 |
| PA confirmed | 101 | 320 | Sensitivity (%) | 24.0 |
| PA excluded | 0 | 275 | Specificity (%) | 100.0 |

The table shows real and predicted diagnosis (PA confirmed vs. excluded), accuracy, sensitivity, specificity for the training cohort (n=522), the validation cohort (n=174), and the combined cohort from Torino (n=696). Diagnostic performance is shown for the PACT (Primary Aldosteronism Confirmatory Testing) score. A cut-off of equal or greater than 5 identifies patients with a confirmed diagnosis of PA with the maximum sensitivity; a cut-off of equal or greater than 8 identifies patients with a confirmed diagnosis of PA with the higher accuracy; a cut-off of equal or greater than 13 identifies patients with a confirmed diagnosis of PA with the maximum specificity.

**Table S7. Distribution of PA patients according to the score**

| **Score Points** | **Total**  (n) | **PA excluded** | | **PA confirmed** | |
| --- | --- | --- | --- | --- | --- |
| (n) | (%) | (n) | (%) |
| 0.0-2.0 | 14 | 14 | 100,0 | 0 | 0,0 |
| 2.1-4.0 | 49 | 49 | 100,0 | 0 | 0,0 |
| 4.1-6.0 | 138 | 106 | 76,8 | 32 | 23,2 |
| 6.1-8.0 | 145 | 63 | 43,4 | 82 | 56,6 |
| 8.1-10.0 | 137 | 25 | 18,2 | 112 | 81,8 |
| 10.1-12.0 | 112 | 18 | 16,1 | 94 | 83,9 |
| 12.1-14.0 | 87 | 0 | 0,0 | 87 | 100,0 |
| 14.1-16.0 | 14 | 0 | 0,0 | 14 | 100,0 |
| Total | 696 | 275 | N.A. | 421 | N.A. |

Number (n) and proportion (%) of patients stratified for diagnosis (PA excluded *vs.* confirmed) is shown according to the score in the developmental cohort of Torino (n=696). N.A., Not Applicable.

**Figure S1. Flow chart for the management of PA patients**

Immagine che contiene screenshot

Descrizione generata automaticamente

Flow chart for the management of patients with a positive screening test (Developmental Cohort + External Validation Cohort; n=1,024). (**A**) PA patient management using the PACT score; the number of patients is indicated in bold; cut-offs are indicated in grey. Misclassified patients are reported in red. (**B**) Confusion matrix representing real and predicted subtype diagnosis, sensitivity, specificity, positive and negative predictive value (PPV; NPV). AVS, Adrenal Venous Sampling; PA, Primary Aldosteronism; LREH, Low Renin Essential Hypertensive patients (PA positive screening test with a negative confirmatory test); PACT, Primary Aldosteronism Confirmatory Testing Score.